Study S003210

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Knee Osteoarthritis (AMAZE 6)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07509307
Acronym: AMAZE 6
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 400
Start: 2026-04-20
Primary completion: 2028-08-14
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity; Overweight; Osteoarthritis, Knee
Interventions: DRUG:NNC0487-0111; DRUG:Placebo (matched to NNC0487-0111)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1313-6954; OTHER:2024-520445-23

Registered primary outcomes

Relative change in body weight [From baseline (week 0) to week 80]
Change in Western Ontario and McMaster Universities Osteoarthritis Index Numerical Rating Scale (NRS) 3.1 (24-hour) (WOMAC) pain score [From baseline (week 0) to week 80]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.